88302
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 4
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.978209575
- umap2_2d
- 1.89707968
- umap1_3d
- -0.252662286
- umap2_3d
- 3.944029085
- umap3_3d
- -1.211371523
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- INTERFERON_GAMMA_RESPONSE+0.400
- G2M_CHECKPOINT+0.310
- E2F_TARGETS+0.280
- MYC_TARGETS_V1+0.270
- PROTEIN_SECRETION+0.270
- MITOTIC_SPINDLE+0.210
- OXIDATIVE_PHOSPHORYLATION+0.210
- IL6_JAK_STAT3_SIGNALING+0.190
- ADIPOGENESIS+0.170
Top 10 suppressed
- ANGIOGENESIS-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- HEDGEHOG_SIGNALING-0.360
- APICAL_SURFACE-0.320
- HYPOXIA-0.310
- MYOGENESIS-0.280
- TNFA_SIGNALING_VIA_NFKB-0.200
- COAGULATION-0.190
- WNT_BETA_CATENIN_SIGNALING-0.170
- APICAL_JUNCTION-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202424 | — | — | 0.833 |
| 2 | R137 | — | — | 0.822 |
| 3 | MNG1021 | — | — | 0.821 |
| 4 | b652254e-228b-40d4-be79-536ad87dad69 | — | — | 0.813 |
| 5 | MNG547 | — | — | 0.803 |
| 6 | TCGA-E9-A22H-01A-11R-A157-07 | — | B | 0.797 |
| 7 | MNG833 | — | — | 0.796 |
| 8 | 004589d9-7eb6-46cb-b822-20cd1939aa7e | — | — | 0.791 |
| 9 | SRR1516083 | — | — | 0.787 |
| 10 | R355 | — | — | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.140 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |